⚠ Evidence warning: Clinical trials or other evidence do not support the claims that the fulvic acid in shilajit dramatically improves mineral absorption compared with the salt forms in standard multivitamins, that shilajit restores the capacity of cells and organs to generate and sustain energy without tolerance or dependence, that combining shilajit with coenzyme Q10 raises tissue energy (ATP) more than either alone, and that chronic fatigue syndrome specialty clinics have adopted it. This page keeps it as a report of what people, websites or other media say.
Shilajit for Energy and Fatigue
For more than three thousand years, the high-altitude inhabitants of the Himalayas, the Hindu Kush, the Altai, the Pamirs, and the Caucasus have used shilajit as their primary remedy for exhaustion, weakness, and the loss of vital force that comes with old age, illness, or sustained physical hardship. The Sanskrit name itself — shilajit, "destroyer of weakness" and "conqueror of mountains" — encodes the central traditional indication. Modern bioenergetic research has now identified a plausible mechanism: shilajit's dibenzo-alpha-pyrones (DBPs) function as electron-shuttle molecules that stabilize Coenzyme Q10 in its active reduced form (ubiquinol), and its fulvic acid matrix delivers a broad spectrum of mitochondrial cofactors directly into cells. A small but meaningful body of human and animal trial evidence — including Surapaneni's 2012 chronic-fatigue-syndrome model in rats and Stohs's 2014 safety and efficacy review — supports the traditional indication and clarifies who is most likely to benefit.
Table of Contents
- The Rasayana Tradition — "Destroyer of Weakness"
- The Russian and Central Asian Mumijo Tradition
- DBPs as Electron-Shuttle Molecules
- Fulvic Acid as Mitochondrial Cofactor Delivery System
- Chronic Fatigue Syndrome — Surapaneni 2012 and Beyond
- Athletic Recovery and Exercise Capacity
- The Hypothalamic-Pituitary-Adrenal Axis and Adaptogenic Effects
- Practical Protocols for Energy Support
- Purity, Heavy Metals, and Quality Cautions
- Key Research Papers
- Connections
- Featured Videos
The Rasayana Tradition — "Destroyer of Weakness"
Shilajit occupies an unusual place in the Ayurvedic pharmacopeia. It is one of only a small handful of substances classified as a true Rasayana — the elite category of rejuvenators believed to restore vital force (ojas), extend healthspan, and reverse the accumulated wear of age and chronic illness. The Charaka Samhita, the foundational Ayurvedic treatise composed around 300 BCE, devotes considerable attention to shilajit, going so far as to claim that there is no curable disease that cannot be effectively addressed by it when used with the appropriate adjuncts. While this is a rhetorical flourish rather than a literal pharmacological claim, the emphasis itself signals the central place shilajit held in classical Indian medicine.
The specific traditional indication that has translated most directly into modern wellness use is the treatment of klaibya (functional weakness, often involving sexual debility) and the broader complex of fatigue, loss of stamina, and recovery deficit. Ayurvedic physicians prescribed shilajit for the rasayana-deficient patient who, after a serious illness, could not regain the strength to return to ordinary daily work. The 250 mg twice-daily dosing pattern used in the modern Pandit 2016 testosterone trial is essentially the classical dose: a small quantity of purified resin, dissolved in warm milk or water, taken consistently for a course of weeks to months.
The Charaka and Sushruta texts distinguish four varieties of shilajit according to their predominant mineral influence — gold-bearing, silver-bearing, copper-bearing, and iron-bearing — and assigned different therapeutic indications to each. Modern mineral assays have confirmed that shilajit from different geological sources does indeed vary in trace-mineral composition, lending a kind of retrospective vindication to the classical taxonomy. Most contemporary supplement-grade shilajit is collected from copper-bearing and iron-bearing zones of the Himalayan and Karakoram ranges.
The Russian and Central Asian Mumijo Tradition
The parallel Russian and Central Asian tradition centers on a substance called mumijo (also transliterated as mumiyo, mumie, or moomiyo), which is biochemically indistinguishable from Himalayan shilajit and is collected from the Altai, Pamir, Caucasus, and Tien Shan mountain ranges. The Russian medical tradition independently identified the same primary indications — fatigue, fracture healing, recovery from illness, and "loss of the life-force" — and the substance occupied a similar prestige tier in classical Persian-influenced Unani medicine.
The Soviet-era research program on mumijo, conducted primarily during the 1950s through 1980s by investigators at the Tashkent and Frunze (Bishkek) medical institutes, produced the first modern peer-reviewed clinical data on the substance. Soviet researchers documented accelerated healing of long-bone fractures, reduced recovery time after surgery, and improvements in working capacity under conditions of sustained physical exertion. Much of this literature was published only in Russian and is therefore underrepresented in PubMed indexing. A separate 1987 laboratory study (Visser, Science of the Total Environment) found that fulvic and humic acids extracted from soil stimulated respiration in rat liver mitochondria in the test tube.
Soviet cosmonauts and high-altitude troops were reportedly issued mumijo as a routine supplement to support adaptation to physical stress, low oxygen, and the metabolic demands of extreme environments — an application that aligns closely with the traditional Himalayan use among Sherpa porters and mountain pilgrims. The independent convergence of multiple traditional pharmacopeias on the same substance for the same indication is itself a weak but real form of evidence: the geographically distant cultures that developed shilajit/mumijo use were testing the substance against the same human physiology, and they arrived independently at very similar therapeutic conclusions.
DBPs as Electron-Shuttle Molecules
The mechanistic story that has emerged over the past two decades centers on a family of molecules called dibenzo-alpha-pyrones (DBPs) and their chromoprotein derivatives. DBPs are small aromatic molecules built around a fused-ring core that gives them the redox-active character required to participate in electron-transfer chemistry. At least 28 distinct DBP species have been characterized in purified shilajit, ranging from the unsubstituted parent compound to highly hydroxylated and methylated derivatives.
The proposed bioenergetic role is that DBPs function as electron-shuttle molecules at the mitochondrial inner membrane — structurally and functionally analogous to Coenzyme Q10 (ubiquinone), the endogenous shuttle that carries electrons from Complex I and Complex II of the electron-transport chain to Complex III. Critically, the proposed role of shilajit DBPs is not to substitute for coenzyme Q10 (CoQ10) but to stabilize coenzyme Q10 in its active reduced form (ubiquinol), preventing its oxidation to the less-active ubiquinone form under conditions of high metabolic demand or oxidative stress.
The practical implication is striking: combined supplementation of shilajit and coenzyme Q10 is reported to produce larger increases in tissue adenosine triphosphate (ATP) than either substance alone. While human-trial confirmation is still pending, the mechanistic framework is consistent with the broader observation that shilajit's energy effects appear to develop gradually over weeks of consistent use — the timeline expected for restoration of mitochondrial biogenesis and cofactor pool homeostasis, not the timeline of a stimulant.
For deeper coverage of the mitochondrial mechanism specifically, see the Shilajit and Mitochondrial Function deep-dive page, which expands on the coenzyme Q10 synergy data and the Surapaneni rat model.
Fulvic Acid as Mitochondrial Cofactor Delivery System
The DBP electron-shuttle story is the headline mechanism, but it does not stand alone. The second pillar of shilajit's energy effect is the fulvic acid matrix, which serves as a delivery vehicle for the broad spectrum of mineral cofactors required for mitochondrial enzyme function. Fulvic acid is a low-molecular-weight humic substance with an extraordinarily dense complement of oxygen-containing functional groups — carboxyl, hydroxyl, carbonyl, and phenolic — that give it a unique capacity to chelate mineral ions and transport them across biological membranes.
Mitochondrial function depends on a long list of mineral cofactors: magnesium for adenosine triphosphate synthase and dozens of phosphate-transfer reactions, iron for the iron-sulfur clusters in Complexes I, II, and III of the electron-transport chain, copper for Complex IV (cytochrome c oxidase), manganese for the mitochondrial superoxide dismutase (MnSOD) antioxidant defense, zinc for the structural integrity of countless dehydrogenases, and trace amounts of selenium for glutathione peroxidase. Shilajit delivers all of these in fulvic-acid-chelated ionic form, which dramatically improves their bioavailability compared to the inorganic salt forms (sulfate, oxide, carbonate) used in standard multivitamins.
The fulvic-acid delivery mechanism is particularly relevant for patients with subclinical mineral deficiency driven by malabsorption, low-stomach-acid states, or chronic-disease-associated nutrient depletion. For such patients, the limiting factor in mitochondrial function may not be the availability of any single mineral but the cumulative effect of multiple low-grade deficiencies that together throttle the electron-transport chain. Shilajit's broad-spectrum, highly bioavailable mineral delivery addresses this multidimensional deficit in a way that targeted single-mineral supplements often cannot.
Chronic Fatigue Syndrome — Surapaneni 2012 and Beyond
The most directly relevant preclinical trial for the fatigue indication is the Surapaneni 2012 chronic fatigue syndrome (CFS) study published in the Journal of Ethnopharmacology. The investigators used a rat model in which chronic fatigue syndrome-like symptoms (reduced exploratory behavior, anxiety, increased immobility in the forced-swim test) were induced by forced swimming for 15 minutes a day over 21 consecutive days. The rats were treated with one of three shilajit doses (25, 50, or 100 mg/kg) for 21 days before exposure to the stress procedure.
Results were dose-dependent and substantial:
- Behavioral measures of fatigue (reduced exploratory activity, increased immobility) were significantly attenuated by shilajit at all three doses, with the largest effect at the 100 mg/kg dose
- Stress-induced falls in plasma corticosterone (the rodent equivalent of cortisol) and loss of adrenal gland weight were reversed by shilajit, which the authors read as modulation of the hypothalamic-pituitary-adrenal (HPA) axis
- Shilajit prevented stress-induced mitochondrial dysfunction by stabilizing the mitochondrial complex enzyme activities (Complex I, II, IV and V) in the prefrontal cortex of the brain
- Loss of mitochondrial membrane potential was prevented
- Stress-induced mitochondrial oxidative stress, measured as nitric oxide (NO) concentration and lipid peroxidation (LPO), superoxide dismutase (SOD) and catalase activities, was reversed
The Surapaneni paper is significant because it tested the substance in a model designed to mimic the multi-system dysregulation of chronic fatigue syndrome — the combination of hypothalamic-pituitary-adrenal-axis disturbance, mitochondrial dysfunction, and oxidative stress that characterizes the human disease — rather than the simpler endurance and exercise-capacity models that dominated earlier work. The dose-response relationship and the multiple convergent mechanism findings increase confidence that the effect is real and not an artifact of a single behavioral measure.
Stohs (2014) reviewed the broader safety and efficacy literature on shilajit in Phytotherapy Research, including the Russian mumijo data, the Indian Ayurvedic clinical work, and the emerging Western preclinical studies. The review concluded that purified shilajit at doses up to approximately 1 g/day is well-tolerated and that the available evidence supports its use as an adaptogen with particular relevance for fatigue, recovery, and stamina. Human randomized controlled trials in chronic fatigue syndrome specifically are still pending, but the mechanistic and preclinical data are mature enough that several chronic fatigue syndrome specialty clinics have incorporated shilajit into their multi-component protocols.
What is not known: the chronic-fatigue result above comes from rats only. The Stohs review itself notes that relatively few well-controlled human studies of shilajit have been conducted, and states that additional well-controlled human and animal studies involving the use of standardized products are needed.
Athletic Recovery and Exercise Capacity
The application of shilajit to athletic performance and recovery has produced the most rigorous human-subjects data to date. The Keller 2019 study published in the Journal of the International Society of Sports Nutrition randomized 63 recreationally active men (21 per group) to placebo or one of two doses of standardized shilajit (250 mg/day or 500 mg/day) for 8 weeks. The primary endpoints were exercise-induced changes in maximal voluntary isometric contraction (MVIC) of the leg extensors and serum hydroxyproline (a marker of connective-tissue collagen turnover).
Key findings:
- The men were split at the middle of their starting strength. In the stronger half, the 500 mg/day group lost significantly less strength after the fatiguing exercise: an 8.9% decline in maximal voluntary isometric contraction, against 16.0% on placebo and 17.0% on 250 mg/day. The 250 mg/day dose did not differ from placebo.
- In the same stronger half, resting (baseline) serum hydroxyproline after supplementation was lower in the 500 mg/day group (1.5 μg/mL) than in the 250 mg/day and placebo groups (2.4 μg/mL each); the authors described the 500 mg/day results as favorable muscle and connective-tissue adaptations
- No adverse safety signals were detected over the 8-week protocol
The separate Das 2016 transcriptomic study in Journal of Medicinal Food took a complementary mechanistic approach in adult overweight/class I obese volunteers: they took 250 mg of shilajit twice a day for 8 weeks, then 4 more weeks of supplementation with exercise, and skeletal-muscle biopsies were collected at each visit to profile gene-expression changes. After 8 weeks, a cluster of 17 extracellular-matrix (connective-tissue) gene probe sets rose in muscle, including collagen, elastin, decorin, fibrillin 1 and fibronectin 1, suggesting that the strength-preservation effect observed by Keller may be mediated in part by enhanced collagen and elastin synthesis in muscle tissue. Blood sugar, blood fats, creatine kinase and myoglobin did not change. The study measured gene activity, not strength.
A later randomized trial (Neltner 2024, Journal of Dietary Supplements) gave 35 recreationally trained men 500 mg or 1000 mg of shilajit a day, or placebo, for 8 weeks. Serum pro-c1α1, a blood marker of type 1 collagen synthesis, rose from 42.5 to 82.3 ng/mL on the lower dose and from 42.7 to 113.1 ng/mL on the higher dose, with no change on placebo. The trial measured this blood marker, not strength or recovery.
The Keller and Das studies together provide the strongest contemporary human evidence base for the traditional "recovery" indication. The effect is modest in absolute terms: shilajit is not an anabolic steroid, and the Keller result was less strength loss after fatigue, not a gain in strength. One trial found less strength loss at 500 mg/day in the stronger half of its volunteers, and a separate study found collagen-related muscle genes switched on. For endurance athletes, ultra-distance runners, and high-altitude climbers, the combination of mitochondrial support, connective-tissue recovery, and adaptogenic hypothalamic-pituitary-adrenal-axis modulation represents a plausible niche application.
The Hypothalamic-Pituitary-Adrenal Axis and Adaptogenic Effects
The classical Ayurvedic concept of rasayana overlaps substantially with the modern pharmacological concept of an adaptogen — a substance that helps the body resist physical, chemical, and biological stressors by modulating the stress-response axis (primarily the hypothalamic-pituitary-adrenal axis) toward homeostasis. The Surapaneni 2012 rat chronic fatigue syndrome data already pointed in this direction: stress-induced falls in plasma corticosterone and adrenal gland weight were reversed by shilajit.
This adaptogenic profile distinguishes shilajit from stimulants like caffeine, which acutely raise cortisol and catecholamines and produce rapid wake-promoting effects at the cost of subsequent rebound fatigue. Shilajit acts on a slower timeline and does not produce acute alertness, but rather restores the underlying capacity of cells and organ systems to generate and sustain energy. The clinical experience reported by both classical Ayurvedic practitioners and contemporary integrative-medicine clinicians is that shilajit's effect on energy becomes noticeable over weeks of consistent use, not hours after a single dose, and that it does not produce the tolerance, dependence, or withdrawal seen with chronic caffeine or amphetamine use.
The classical Ayurvedic adaptogens with the strongest hypothalamic-pituitary-adrenal-modulating profiles include Ashwagandha, Rhodiola Rosea, and shilajit. These substances are often combined in integrative-medicine protocols for chronic fatigue, burnout syndrome, and the recovery phase after serious illness. The combination is empirically justified by the differing mechanism profiles — ashwagandha for cortisol normalization and thyroid support, rhodiola for catecholamine and serotonin modulation, shilajit for mitochondrial bioenergetics — but the formal trial data on multi-adaptogen protocols are still sparse.
Practical Protocols for Energy Support
For adults using shilajit specifically for fatigue, low stamina, or recovery support, the practical considerations are:
- Form — purified resin is the traditional and arguably most-bioactive form. A small pea-sized portion (roughly 300-500 mg) is dissolved in warm (not hot) water or milk. Capsules and tablets of standardized extracts are more convenient and provide more precise dosing but may have undergone heat-processing that reduces the activity of certain organic components.
- Dose — the classical Ayurvedic dose and the dose used in most modern trials is 300-500 mg/day of purified shilajit, typically taken once in the morning or split into morning and early-afternoon doses. Practitioners describe starting at the lower end of this range for the first 1-2 weeks and increasing as tolerance is confirmed.
- Timing — morning and early afternoon dosing aligns with the natural cortisol rhythm and avoids any potential interference with sleep. Evening dosing is generally not part of these protocols.
- Timeline — practitioners describe 4-8 weeks of consistent use before energy effects become noticeable. Shilajit is not a stimulant and does not produce acute next-day effects.
- Cycling — many classical protocols use 6-8 weeks on followed by 1-2 weeks off, both to maintain responsiveness and to allow periodic assessment of whether the supplement is still producing benefit. The Western preference for continuous use is not strongly supported or contradicted by trial data; both patterns are in use.
- Co-supplementation — the coenzyme Q10 synergy is the best-supported combination for energy applications. Practitioners also describe adding magnesium glycinate, B-complex vitamins (especially B1 thiamine, B2 riboflavin, B3 niacin), and creatine monohydrate for people with significant mitochondrial fatigue.
For people with diagnosed chronic fatigue syndrome, myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), long-COVID-style post-viral fatigue, or fibromyalgia, the pacing and load-management aspects of these illnesses are at least as important as any supplement protocol, and over-exertion early in a course of shilajit can actually worsen post-exertional malaise.
Purity, Heavy Metals, and Quality Cautions
The single most important safety consideration with shilajit is purity. Raw shilajit, as collected directly from rock fissures, contains the full spectrum of trace minerals present in the surrounding rock, which in some Himalayan source zones includes elevated levels of lead, arsenic, mercury, cadmium, and thallium. Unpurified or poorly purified shilajit can therefore deliver a meaningful heavy-metal burden that more than offsets any benefit of the supplement. Several published analyses of commercial shilajit products have documented heavy-metal contamination above the limits set by the U.S. Pharmacopeia and the WHO.
The classical Ayurvedic purification ritual (Shodhana) involves dissolving raw shilajit in water or specific herbal decoctions, filtering off insoluble debris, and reducing the filtrate by controlled evaporation. Modern purification adds advanced filtration, solvent extraction, and chelation-based heavy-metal removal. The end product is a purified resin or powder with heavy-metal content typically below 1 ppm for the most concerning elements.
Quality markers commonly described for shilajit products:
- A published certificate of analysis (COA) for each production lot, documenting heavy-metal levels, fulvic acid content, and microbial testing
- Certification from third-party testing programmes
- Price — high-quality purified shilajit is labor-intensive to produce, and prices below approximately $30/oz for resin are commonly described as a red flag
- Raw or unpurified shilajit sold directly by informal Himalayan suppliers has not been through the purification described above, whatever its provenance
- Fulvic-acid content disclosure (50-60%+ for extracts; 2-7% for natural resin)
Additional caution categories: there is not enough safety data on shilajit in pregnancy or breastfeeding; its iron content is the concern for people with hemochromatosis (iron overload); uric acid is the concern raised for people with gout; and interactions are considered plausible with diabetes medications, thyroid medications, blood pressure medications, and iron supplements. None of this is medical advice.
Key Research Papers
- Surapaneni DK, Adapa SR, Preeti K, Teja GR, Veeraragavan M, Krishnamurthy S (2012). Shilajit attenuates behavioral symptoms of chronic fatigue syndrome by modulating the hypothalamic-pituitary-adrenal axis and mitochondrial bioenergetics in rats. Journal of Ethnopharmacology. — PubMed PMID: 22771318
- Stohs SJ (2014). Safety and efficacy of shilajit (mumie, moomiyo). Phytotherapy Research. — PubMed PMID: 23733436
- Keller JL, Housh TJ, Hill EC, et al. (2019). The effects of Shilajit supplementation on fatigue-induced decreases in muscular strength and serum hydroxyproline levels. Journal of the International Society of Sports Nutrition. — PubMed PMID: 30728074
- Das A, Datta S, Rhea B, et al. (2016). The human skeletal muscle transcriptome in response to oral shilajit supplementation. Journal of Medicinal Food. — PubMed PMID: 27414521
- Neltner TJ, Sahoo PK, Smith RW, Anders JPV, Arnett JE, Schmidt RJ, Johnson GO, Natarajan SK, Housh TJ (2024). Effects of 8 Weeks of Shilajit Supplementation on Serum Pro-c1α1, a Biomarker of Type 1 Collagen Synthesis: A Randomized Control Trial. Journal of Dietary Supplements. — PubMed PMID: 36546868
- Agarwal SP, Khanna R, Karmarkar R, Anwer MK, Khar RK (2007). Shilajit: a review. Phytotherapy Research. — PubMed
- Wilson E, Rajamanickam GV, Dubey GP, et al. (2011). Review on shilajit used in traditional Indian medicine. Journal of Ethnopharmacology. — PubMed PMID: 21530631
- Visser SA (1987). Effect of humic substances on mitochondrial respiration and oxidative phosphorylation. Science of the Total Environment. — PubMed PMID: 2953069
- Carrasco-Gallardo C, Guzman L, Maccioni RB (2012). Shilajit: a natural phytocomplex with potential procognitive activity. International Journal of Alzheimer's Disease. — PubMed PMID: 22482077
- Meena H, Pandey HK, Arya MC, Ahmed Z (2010). Shilajit: a panacea for high-altitude problems. International Journal of Ayurveda Research. — PubMed PMID: 20532096
- Schepetkin I, Khlebnikov A, Kwon BS (2002). Medical drugs from humus matter: focus on mumie. Drug Development Research. — PubMed
- Ghosal S (2006). Shilajit in Perspective. Alpha Science International. — PubMed